Asana BioSciences, LLC

Biopharmaceutical venture capital fundraising is on the rise in 2024, boosted in part by surging numbers of $100m-plus mega-rounds, including a pair of large financings that ended June and started Jul

LEO Pharma A/S has hit the mark a second time in a clinical trial program meant to expand its competitive positioning in dermatology with the news that a second Phase III study of its topical JAK inh

Erasca Inc. launched at the end of 2018 with $42m, a high-profile CEO and undisclosed precision oncology programs with the ambitious goal of “erasing cancer.” Even after raising another $200m in Apri

Japan has granted the first approval worldwide for a Janus kinase (JAK) inhibitor in topical form, issuing a nod for Japan Tobacco Inc. ’s Corectim (delgocitinib; JTE-052) in the second-line treatmen